Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study

ABSTRACT Allergic asthma, characterized by airborne allergen sensitivity and Th2 immune responses, is a common and increasing global health concern. Omalizumab, while effective, has limitations such as weight‐ and IgE‐dependent dosing regimens. JYB1904, a recombinant anti‐IgE humanized monoclonal an...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhen‐Wei Shen, Ting‐Han Jin, Kai‐Qi Wu, Jie Zhao, Qi Jiang, Tong Guo, Liang Li, Xiao‐Hua Feng, Pei‐pei Liu, Gui‐Ling Chen
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Clinical and Translational Science
Subjects:
allergic asthma
free IgE suppression
JYB1904
pharmacodynamics
pharmacokinetics
phase Ia trial
Online Access:https://doi.org/10.1111/cts.70264
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70264

Similar Items